diabetes mellitus
Conditions
Interventions
treat the subjects with maximum dose of 0.9mg per day of liraglutide
Sponsors
Kanazawa University, Graduate School of Internal Medicine, department of internal medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) type 2 diabetes, aged >30 years old, and treated with insulin for more than five years; 2) no use of incretin-based therapy at baseline; 3) tolerable to daily injection of liraglutide; 4) preserved left ventricular ejection fraction (LVEF greater than equal to 40%); 5) no symptomatic heart failure; 6) no history of heart failure admission; 7) no coronary intervention within three years; and 8) no critical primary heart disease, including ventricular arrhythmias, persistent atrial fibrillation, complete atrioventricular block, cardiomyopathy, and valvular disease.
Exclusion criteria
Exclusion criteria: 1) endocrine disorders, including type-1 diabetes; 2) refractory malignant tumors; 3) dependency on hemodialysis; and 4) severe hepatic dysfunction (Child-Pugh score greater than equal to 10).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| cardiac function on UCG 6 months after the liraglutide introduction | — |
Secondary
| Measure | Time frame |
|---|---|
| HbA1c, fasting blood glucose, fasting plasma CPR, urinary CPR, fasting glucagon, T-cho, TG, LDL-C, small dense LDL, pre-beta1HDL | — |
Countries
Japan
Contacts
Public ContactKunimasa Yagi
Kanazawa University Hospital department of endocrinology and metabolism
Outcome results
None listed